Acute liver necrosis induced by iodine-131-MIBG in the treatment of metastatic carcinoid tumors.
Iodine-131-metaiodobenzylguanidine (MIBG) is used in the treatment of carcinoid tumors. Temporary palliation with complete subjective symptomatic response has been reported in these patients. This treatment is usually well tolerated and side-effects are generally limited to nausea, mild hepatic toxicity with spontaneous recovery and temporary myelosuppression. Our case report shows that repeated treatment with [131I]MIBG in a patient with extensive carcinoid liver metastasis may cause severe hepatic toxicity leading to death. Factors such as concomitant use of 5-fluorouracil and the progressive nature of the disease may have contributed to this event.
Bongers
V
V
Department of Nuclear Medicine, University Hospital Utrecht, The Netherlands.
de Klerk
J M
JM
Zonnenberg
B A
BA
de Kort
G
G
Lips
C J
CJ
van Rijk
P P
PP
D019797:3-Iodobenzylguanidine; D000208:Acute Disease; D002276:Carcinoid Tumor / Q000000981:diagnostic imaging / Q000532:radiotherapy / Q000556:secondary*; D006801:Humans; D007457:Iodine Radioisotopes / Q000009:adverse effects* / Q000627:therapeutic use; D007462:Iodobenzenes / Q000009:adverse effects* / Q000627:therapeutic use; D008099:Liver / Q000187:drug effects* / Q000473:pathology; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000532:radiotherapy / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D009336:Necrosis; D010166:Palliative Care; D011877:Radionuclide Imaging
D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D019797:3-Iodobenzylguanidine